Amyloid-targeting Alzheimer’s drugs fall short on patient benefit, review finds
A Cochrane review of 17 trials with over 20,000 people with mild cognitive impairment or early dementia found that seven anti-amyloid drugs, including donanemab and lecanemab, do not deliver a clinically meaningful benefit, even though they reduce brain amyloid. The findings challenge the idea that removing amyloid improves patient outcomes and have fueled ongoing debate over the amyloid hypothesis and the drugs’ high costs and risks.
